112 related articles for article (PubMed ID: 12915870)
1. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia.
Gordois A; Scuffham P; Warren E; Ward S
Br J Cancer; 2003 Aug; 89(4):634-40. PubMed ID: 12915870
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
Warren E; Ward S; Gordois A; Scuffham P
Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
[TBL] [Abstract][Full Text] [Related]
3. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
Breitscheidel L
J Med Econ; 2008; 11(4):571-84. PubMed ID: 19450068
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP).
Chen Z; Wang C; Xu X; Feng W
Value Health; 2009; 12 Suppl 3():S85-8. PubMed ID: 20586990
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
Ghatnekar O; Hjalte F; Taylor M
Acta Oncol; 2010 Aug; 49(6):851-8. PubMed ID: 20615173
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
Sanon M; Taylor DC; Parthan A; Coombs J; Paolantonio M; Sasane M
J Med Econ; 2013; 16(1):150-9. PubMed ID: 22762291
[TBL] [Abstract][Full Text] [Related]
8. Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
Goldman J
Nat Clin Pract Oncol; 2005 Mar; 2(3):126-7. PubMed ID: 16264901
[No Abstract] [Full Text] [Related]
9. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M
J Clin Oncol; 2005 Jun; 23(18):4100-9. PubMed ID: 15867198
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
11. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.
Skrepnek GH; Ballard EE
Pharmacotherapy; 2005 Mar; 25(3):325-34. PubMed ID: 15843279
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy of imatinib mesylate for 124 patients with chronic myeloid leukemia in accelerated and blastic phase].
Jiang Q; Chen SS; Jiang B; Jiang H; Qiu JY; Liu YR; Zhang Y; Qin YQ; Lu Y; Huang XJ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):721-6. PubMed ID: 18457260
[TBL] [Abstract][Full Text] [Related]
13. [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].
Voglová J; Poznarová A; Chrobák L; Rabasová J; Beránek M; Moravcová J; Faber E; Klamová H; Cikhart M
Vnitr Lek; 2004 Jan; 50(1):21-3, 26-9. PubMed ID: 15015226
[TBL] [Abstract][Full Text] [Related]
14. [Prognosis factors in imatinib mesilate therapy in patients with a chronic phase of Ph-positive chronic myeloid leukemia: data from a multicenter non-randomized trial in Russia].
Zaritskiĭ AIu; Lomaia EG; Vinogradova OIu; Druzhkova GA; Kolosheĭnova TI; Loria SS; Pospelova TI; Krylova IV; Kruglov SS; Kuznetsov SV; Chelysheva EIu; Abakumov EM; Sokolova MA; Nemchenko IS; Zakharova ES; Goriacheva SR; Kolosova LIu; Vakhrusheva MV; Liamkina AS; Chernova OA; Machiulaĭtene ER; Ivanova VL; Udal'eva VIu; Shneĭder TV; Ogorodnikova IuS; Zhuravlev VS; Zakharova AV; Martynkevich IS; Domracheva EV; Afanas'ev BV; Abdulkadyrov KM; Kovaleva LG; Khoroshko ND; Turkina AG
Ter Arkh; 2007; 79(8):17-22. PubMed ID: 17926465
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
Dalziel K; Round A; Stein K; Garside R; Price A
Health Technol Assess; 2004 Jul; 8(28):iii, 1-120. PubMed ID: 15245690
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.
Hoyle M; Rogers G; Moxham T; Liu Z; Stein K
Value Health; 2011 Dec; 14(8):1057-67. PubMed ID: 22152175
[TBL] [Abstract][Full Text] [Related]
17. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia.
Dalziel K; Round A; Garside R; Stein K
Pharmacoeconomics; 2005; 23(5):515-26. PubMed ID: 15896102
[TBL] [Abstract][Full Text] [Related]
19. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
Wodarz D
Med Hypotheses; 2008; 70(1):128-36. PubMed ID: 17566666
[TBL] [Abstract][Full Text] [Related]
20. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A
Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]